JUXTAPID is only available through the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program.

All prescribers of JUXTAPID must become certified in the JUXTAPID REMS Program. The 3-step process for prescriber certification is outlined below.

1. REVIEW the JUXTAPID Prescribing Information and JUXTAPID REMS Program Fact Sheet

2. COMPLETE the online JUXTAPID REMS Program Prescriber Training Module and JUXTAPID REMS Program Prescriber Enrollment Form

3. AGREE to counsel each patient using the Patient Guide, and to complete a JUXTAPID REMS Program Patient-Prescriber Acknowledgement Form with each patient
By signing this form, I attest that:

- I understand that JUXTAPID® (lomitapide) capsules is only available through the JUXTAPID REMS Program and that I must comply with the program requirements in order to prescribe JUXTAPID.

Use:

- I understand that JUXTAPID is only indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL-apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
- I understand that the safety and effectiveness of JUXTAPID has not been established in patients with hypercholesterolemia who do not have HoFH, including those with heterozygous familial hypercholesterolemia (HeFH).

Hepatotoxicity Risk:

- I understand that there is a risk of hepatotoxicity associated with JUXTAPID.
- I understand the Recommendations for Monitoring of Transaminases with JUXTAPID treatment:
  - Measure serum ALT, AST, alkaline phosphatase and total bilirubin before initiating therapy with JUXTAPID.
  - During the first year of treatment, liver-related laboratory tests (ALT and AST at a minimum) must be measured prior to each increase in dose or monthly, whichever comes first.
  - After the first year, these parameters should be measured at least every 3 months and before any increase in dose.

REMS Program Requirements:

- I have reviewed the JUXTAPID Prescribing Information and the JUXTAPID REMS Program Fact Sheet.
- I have completed the JUXTAPID REMS Program Prescriber Training Module including the Knowledge Assessment for Healthcare Providers.
- I agree to counsel patients on the approved indication for use in patients with HoFH, the risk of hepatotoxicity with JUXTAPID and the need for regular monitoring using the JUXTAPID REMS Patient Guide.
- I agree to complete and sign the Patient-Prescriber Acknowledgement Form with the patient.
- I agree to complete and sign the JUXTAPID REMS Prescription Authorization Form for each prescription.
- I agree that personnel from the JUXTAPID REMS Program may contact me to gather further information or resolve discrepancies or to provide other information related to JUXTAPID or the JUXTAPID REMS Program.
- I agree that Aegerion, its agents and contractors such as the pharmacy providers may contact me via phone, mail, or email to survey me on the effectiveness of the program requirements for the JUXTAPID REMS Program.

Prescriber Signature: ___________________________ Date: ___________________________

Prescriber Name: ___________________________ Phone: ___________________________
Note to Reviewer:

The Juxtapid Prescriber Training and Knowledge Assessment can be accessed online by clicking the link on the website. The participant will need to register to enter the training and knowledge assessment module.

Participants will be required to enter their name, practice name, city, state and zip code and NPI number. The participant’s email address will be requested, if this is not provided the participant will be able to continue.